

# William P Tew

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/55283/publications.pdf>

Version: 2024-02-01

65  
papers

6,014  
citations

218592

26  
h-index

118793

62  
g-index

66  
all docs

66  
docs citations

66  
times ranked

6048  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 164, 12-17.	0.6	6
2	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates. <i>Cornea</i> , 2022, 41, 792-801.	0.9	6
3	Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers. <i>Oncologist</i> , 2022, 27, e37-e44.	1.9	2
4	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2138-2147.	0.8	40
5	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	0.6	9
6	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021, 113, 820-822.	3.0	7
7	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	0.6	2
8	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. <i>Gynecologic Oncology</i> , 2021, 160, 71-76.	0.6	9
9	Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 608-618.	0.8	72
10	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	0.6	2
11	From Assessment to Implementation and Beyond in Cancer and Aging Research. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.00317.	0.8	7
12	Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 853-860.	0.2	1
13	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	0.6	14
14	Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy. <i>JCO Oncology Practice</i> , 2021, 17, e740-e752.	1.4	14
15	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	0.6	18
16	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2594-2604.	0.8	66
17	A nutritional management algorithm in older patients with locally advanced esophageal cancer. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	2
18	Non-exenterative surgical management of recurrent endometrial carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 268-276.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Isolated splenic high-grade serous carcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100818.	0.3	0
20	Goals of care conversations and telemedicine. <i>Journal of Geriatric Oncology</i> , 2021, 12, 995-999.	0.5	6
21	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 78-92.	157.7	230
22	Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study. <i>BMC Women's Health</i> , 2021, 21, 376.	0.8	1
23	The association between social support and chemotherapy-related toxicity in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 274-279.	0.5	9
24	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <i>Cancer</i> , 2020, 126, 1274-1282.	2.0	37
25	Association between a cognitive screening test and severe chemotherapy toxicity in older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 284-289.	0.5	18
26	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	1.2	29
27	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 214-221.	0.6	2
28	Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors. <i>Cancer</i> , 2020, 126, 1708-1716.	2.0	22
29	Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. <i>Journal of Geriatric Oncology</i> , 2020, 11, 753-760.	0.5	34
30	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	1.2	7
31	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22
32	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , 2019, 15, 2463-2470.	1.1	12
33	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	0.6	24
34	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	0.6	24
35	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	0.6	33
36	Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 2326-2347.	0.8	958

#	ARTICLE	IF	CITATIONS
37	Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2018, 151, 257-263.	0.6	20
38	Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2018, 150, 300-305.	0.6	17
39	Association between patient-reported hearing and visual impairments and functional, psychological, and cognitive status among older adults with cancer. <i>Cancer</i> , 2018, 124, 3249-3256.	2.0	21
40	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	3.2	100
41	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 459-467.	0.6	61
42	Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. <i>Gynecologic Oncology</i> , 2017, 146, 101-108.	0.6	32
43	Indications for and complications of transfusion and the management of gynecologic malignancies. <i>Gynecologic Oncology</i> , 2017, 146, 416-426.	0.6	18
44	Development of a Geriatric Service in a Cancer Center: Lessons Learned. <i>Journal of Oncology Practice</i> , 2017, 13, 107-112.	2.5	21
45	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1357-1370.	2.3	82
46	Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2366-2371.	0.8	497
47	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	0.8	318
48	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	0.6	208
49	Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. <i>Cancer</i> , 2016, 122, 3865-3872.	2.0	148
50	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 217-224.	0.6	42
51	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016, 23, 989-993.	0.7	44
52	Anemia and Functional Disability in Older Adults With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1233-1239.	2.3	20
53	Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 3826-3833.	0.8	343
54	The relationship between age, anxiety, and depression in older adults with cancer. <i>Psycho-Oncology</i> , 2015, 24, 712-717.	1.0	103

#	ARTICLE	IF	CITATIONS
55	Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study. <i>Cancer</i> , 2014, 120, 335-343.	2.0	49
56	Considerations Regarding the Administration of Systemic Therapy for Elderly Patients With Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 1-11.	1.3	4
57	CA125 Level Association With Chemotherapy Toxicity and Functional Status in Older Women With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1022-1028.	1.2	12
58	Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3457-3465.	0.8	1,501
59	Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401. <i>Journal of Clinical Oncology</i> , 2011, 29, 1290-1296.	0.8	318
60	Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 358-366.	3.2	92
61	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. <i>Investigational New Drugs</i> , 2009, 27, 366-373.	1.2	4
62	Ovarian Cancer in Older Women. <i>Seminars in Oncology</i> , 2008, 35, 582-589.	0.8	21
63	Mentoring Junior Faculty in Geriatric Oncology: Report From the Cancer and Aging Research Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 3125-3127.	0.8	38
64	Unusual Tumors of the Colon, Rectum and Anus. , 2006, , 401-409.		0
65	Targeted Therapies for Esophageal Cancer. <i>Oncologist</i> , 2005, 10, 590-601.	1.9	128